Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $38.69.
Several equities research analysts have recently issued reports on VRDN shares. Wells Fargo & Company upgraded Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $31.00 in a report on Monday, June 29th. The Goldman Sachs Group reiterated a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Truist Financial raised their price target on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Wedbush lifted their price target on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th.
Insider Activity
Hedge Funds Weigh In On Viridian Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of VRDN. Integrated Wealth Concepts LLC acquired a new position in shares of Viridian Therapeutics in the 2nd quarter valued at $33,000. Squarepoint Ops LLC increased its holdings in shares of Viridian Therapeutics by 303.0% during the 2nd quarter. Squarepoint Ops LLC now owns 176,955 shares of the company’s stock worth $3,251,000 after buying an additional 133,046 shares during the last quarter. Arizona State Retirement System raised its position in shares of Viridian Therapeutics by 19.2% in the 2nd quarter. Arizona State Retirement System now owns 21,330 shares of the company’s stock worth $392,000 after buying an additional 3,431 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Viridian Therapeutics in the 2nd quarter worth $204,000. Finally, Headlands Technologies LLC boosted its holdings in Viridian Therapeutics by 40.1% in the second quarter. Headlands Technologies LLC now owns 46,544 shares of the company’s stock valued at $855,000 after acquiring an additional 13,321 shares during the last quarter.
Viridian Therapeutics Price Performance
Viridian Therapeutics stock opened at $19.40 on Wednesday. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The stock has a market capitalization of $2.20 billion, a P/E ratio of -5.76 and a beta of 1.11. The firm’s 50-day moving average is $22.03 and its two-hundred day moving average is $19.43. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The firm had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts predict that Viridian Therapeutics will post -4.07 earnings per share for the current year.
About Viridian Therapeutics
Viridian Therapeutics, Inc (NASDAQ:VRDN) is a clinical-stage biotechnology company focused on developing treatments for autoimmune and inflammatory diseases. The company’s primary research centers on antibody-based medicines designed to target the insulin-like growth factor 1 receptor (IGF-1R), a biological pathway associated with thyroid eye disease (TED).
Viridian’s pipeline includes veligrotug, an investigational monoclonal antibody being developed for TED, as well as additional drug candidates intended to provide alternative dosing options and potentially address broader autoimmune conditions.
Featured Articles
- Five stocks we like better than Viridian Therapeutics
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
